在瘤学药物开发中的剂量优化:营销后要求和承诺的风险因素
Hiroe Kitagaki1,2, Kentaro Takeda3, Kazuya Murai1,4
1Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University, Tokyo, Japan.
Clinical pharmacology and therapeutics
|May 21, 2025
概括
乐观计划指导瘤学药物剂量,但这项研究确定了风险. 在最大耐受水平下剂量增加不良事件和批准后剂量优化需求,为更好的早期试验设计提供信息.
科学领域:
- 瘤学 药物开发 药物开发
- 临床药理学 临床药理学
- 监管科学 监管科学
背景情况:
- 传统的瘤药物剂量采用"越高越好"的方法.
- 针对性药物和免疫疗法等较新的疗法需要在剂量选择方面进行范式转变.
- 美国食品和药物管理局 (FDA) 在2021年启动了Project Optimus,以改革瘤学中的剂量优化.
研究的目的:
- 确定新批准的瘤药物剂量优化相关的营销后要求或承诺的风险因素.
- 为设计更有效的早期临床试验提供数据驱动的见解.
- 通过根据早期临床数据确定谨慎的方法来补充现有的FDA Project Optimus指导.
主要方法:
- 在长时间内对新批准的瘤药物进行全面分析.
- 后勤回归分析,以确定营销后剂量优化的风险因素.
- 评估标记剂量,最大耐受剂量,不良反应和暴露安全概况之间的关系.
主要成果:
- 当标注剂量等于最大耐受剂量时,副作用的百分比增加,导致治疗中止.
- 建立暴露与安全的关系增加了市场营销后要求或剂量优化承诺的风险.
- 特定的早期临床数据点与需要营销后剂量调整的可能性更高有关.
结论:
- 该研究确定了关键的风险因素,这些风险因素需要在瘤药物开发中对剂量优化采取更谨慎的方法.
- 结果提供客观,定量见解,以指导早期试验设计和剂量选择策略.
- 这项研究支持正在进行的努力,以完善瘤药物开发范式,与最佳项目目标保持一致.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10.9K
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.0K
相关概念视频
Pharmacovigilance
762
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
762
Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Drug Dosage Regimen: Overview
3.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.4K
Preclinical Development: Overview
4.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.1K
Clinical Trials: Overview
2.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.6K
